ARDS makes you feel like you cant breathe, like youre suffocating, said Eileen Rubin, J.D., ARDS survivor and Founder of the ARDS Foundation.
Acute respiratory distress syndrome (ARDS) is as scary as it sounds. A person is usually sick with something else, such as the flu, COVID-19, or sepsis (a serious bloodstream bacterial infection), before they develop ARDS. Suddenly, the person has trouble breathing, is short of breath, and feels like they are suffocating. ARDS patients quickly go into respiratory distress and usually need to be put on a ventilator (and are typically put into a medically induced coma) to get them the oxygen they so desperately need.
Within about two days in the hospital, I went into respiratory arrest and was diagnosed with ARDS at age 33, Rubin explained. I spent nine weeks in the hospital, eight weeks on a ventilator, and four weeks in a medically induced coma.
Despite the seriousness of ARDS, Rubin wants those affected by the disease and their families to know there is hope. Over 50% of the almost 200,000 Americans diagnosed with ARDS each year recover and it is not a terminal illness.
ARDS patients are given the grim statistics about what is going to happen to them and how dire it is, she added. Where there is life, there is hope families should talk to their ARDS loved one if theyre in a coma, tell them the reasons they need to have hope and focus on the things they need to survive for.
This year, more people will be diagnosed with ARDS due to COVID-19. ARDS tends to develop in severely ill COVID-19 patients and is a common cause of death in these critical patients.
Rubin told BioSpace how her ARDS experience prompted her to help others by creating the ARDS Foundation. We also spoke to Gil Van Bokkelen, Ph.D., CEO of Athersys, a company developing stem cell therapy to treat ARDS, which is currently being tested in COVID-19 patients who develop ARDS.
Eileen Rubin, J.D., ARDS survivor and founder of the ARDS Foundation (left) and Gil Van Bokkelen, Ph.D., Chairman and CEO of Athersys (right). Source: Eileen Rubin and Athersys.
Eileens story: I cant breathe. I think Im dying.
It all started with lower back pain not something you think would land you in the hospital on a ventilator, fighting for your life days later.
I was suffering from excruciating lower back pain for eight days before going to my doctor, Rubin explained. They said I likely pulled a muscle, prescribed me a muscle relaxant, and sent me home.
A week later, she still felt horrible and was having difficulty breathing. She saw another doctor, who basically said the same thing and didnt order any tests, sending her home with the same muscle relaxer.
The next morning, she awoke around 5:00 a.m. with labored breathing and difficulty walking. After calling her doctor, they said they wouldnt see her again because they had just seen her yesterday. Frustrated and scared, she found another doctor who saw her later that afternoon. By then, her blood pressure was dangerously low (70/50), she had blood in her urine and she became delirious. This third doctor finally ordered bloodwork and a chest x-ray but sent her home to await the results.
She awoke very early the next morning to a phone call from the doctor telling her to go to the emergency room immediately her white blood cell count was 3.5 times higher than normal. Once in the emergency room, she saw a pulmonologist who said she would need to be ventilated if her breathing got any worse. That night, her kidneys failed. Luckily, she was stabilized, but during her second day in the hospital, she became extremely short of breath.
I said to my mother, I cant breathe. I think Im dying. And my mother ran out of the room, Rubin recounted. My mother rushed to find my internist and repeated what I had said. My internist said, Shes okay, I just saw her. Shes just anxious. My mother replied, Listen, she just said this, and I need you to come see her now. So, the doctor came in and saw me.
Upon realizing how badly Rubin was doing, her doctor cleared the room, called a code and declared that she was in respiratory arrest. Almost three hours later, her family was let back into her room, only to find her ventilated in a medically induced coma.
Unfortunately, this pain denial isnt uncommon pain that women experience is far too often downplayed, not taken seriously, or outright dismissed in healthcare.
A woman in her 30s says she has pain in her chest and is having difficulty breathing is seen totally differently than a man with the same symptoms, Rubin noted. My doctors didnt even consider doing an EKG.
After receiving many units of blood, having her lungs collapse multiple times, developing some hospital-acquired infections and having five chest tubes placed, she was sent home to slowly recover after nine weeks in the hospital. Read her entire battle with ARDS, From Trial Attorney to Life Support in Only Days, on the ARDS Foundation website.
A few years after recovering from her battle with ARDS, Rubin wanted to help other ARDS patients and their families, providing the information and support that she and her family didnt have.
When my sister went on the internet, all she got were medical articles filled with jargon and autopsy photos, Rubin commented. There was nothing positive written about ARDS, nothing that offered any support.
Rubin wanted to change that, so she created the ARDS Foundation in 2000. The foundation initially started to create a simple, easy to understand brochure for families explaining what ARDS is. Today, it is a nonprofit organization offering support, information, and awareness of ARDS to patients and families.
After ARDS, a lot of people become less outgoing, more reserved, Rubin noted. They dont feel like doing certain things and their personality changes they may suffer from anxiety, depression, or PTSD because their life is completely altered.
The foundation is also facilitating medical research to improve ARDS care and treatment.
My ARDS was treated much like it is today, with supportive therapy and ventilation there is no specific treatment for ARDS, Rubin explained. My doctors were just trying to put out all the fires that were going on while I was critically ill.
A stem cell therapy for ARDS
One company working towards an ARDS treatment is Athersys, a biotech company focusing on regenerative medicine therapies for diseases with significant unmet need. Their product, called MultiStem, is a certain type of off-the-shelf human stem cell being studied to treat a wide array of conditions, including neurological, cardiovascular, inflammatory, and immune diseases.
A vial of MultiStem cells. Source: Athersys
To make this therapy, stem cells are isolated from the bone marrow of healthy donors and separated to collect a certain population of cells called multipotent adult progenitor cells (MAPC). These specific stem cells are expanded in the lab to become MultiStem; they can be frozen for extended periods of time, ready for use when a patient needs them.
These cells have a robust and highly distinctive expansion potential material from a single donor can be used to produce millions of doses, which is well beyond the limits of other donor-derived cell types, explained Van Bokkelen.
MultiStem cells dont express molecules that would elicit a rejection response, meaning they dont require donor-recipient matching or immune suppression when being given to the patient. The cells can be used like a universal donor Type O blood product, Van Bokkelen added.
Because of the time sensitive nature of the conditions MultiStem is being used to treat (ARDS, stroke, trauma), timing is everything; being able to simply thaw ready-to-use cells and administer them to the recipient rapidly is key. Once the cells are delivered into the patient, they express a range of proteins and immune factors, giving the cells a unique drug-like profile.
Were administering living cells that are dynamically responsive to the signals and cues produced by the human body, unlike traditional pharmaceuticals or biologics that are designed to do one very specific thing, said Van Bokkelen. MultiStem is a living multifactor delivery system the cells home to sites of tissue damage and inflammation where they perform a whole series of actions.
When a virus like COVID-19 or another pathogen enters the body, the immune system becomes activated to destroy the pathogen. Sometimes, a hyperactive, over inflammatory state is triggered, which can actually be counterproductive and harmful. In fact, this cytokine storm is thought to cause ARDS in severe COVID-19 patients, resulting in the need for ventilation and frequently leading to death among seriously and critically ill individuals.
If we administer MultiStem cells to patients in this hyperinflammatory state, the cells will home to the spleen, the warehouse of activated immune cells, and calm everything down, restoring immunological homeostasis, Van Bokkelen explained. MultiStem cells dont just regulate one type of cell, they regulate a whole series of pathways that is what makes them so powerful.
Once the overactive immune response has been reigned in, the body is able to recover and heal faster, rather than spiraling out of control.
You might be thinking, If we have these stem cells inside us already, why wouldnt they do the same thing and tamp down the overactive immune response in the first place? While a person in the throws of a hyperactive immune response may have some of these specific stem cells (usually there is a very small amount in the bone marrow), they are slow to mobilize and there may not be enough to balance out the storm of activated immune cells.
If someone sustains a serious injury and theyre losing lots of blood, we give those patients a blood transfusion, Van Bokkelen posed. Its not that the body cant make red blood cells, its just that it cant do it fast enough to deal with the rapid blood loss. Similarly, we can administer MultiStem to a patient much faster than the body would be able to respond on its own, helping to get things back to where we want them to be.
A similar situation happens during a hyperactive immune response administering MultiStem to provide the body with more calming stem cells helps balance the immune response quickly to avoid damage to the patient.
Another bonus of these cells is that they have a finite half-life in the body; unlike a bone marrow transplant that replaces the bone marrow permanently, MultiStem cells are cleared over time just like other normal cells in the body.
MultiStem cells to treat COVID-19-induced ARDS
When COVID-19 appeared, the Athersys team thought MultiStem may be helpful for ARDS in COVID-19 patients because it had already been tested in ARDS animal models and clinical studies. Previously, MultiStem, delivered either intravenously or directly to the lungs (endobronchially), effectively treated ARDS in sheep alone and in conjunction with extracorporeal membrane oxygen (ECMO).
Athersys concluded a randomized, double-blind, placebo-controlled Phase I/II study (MUST-ARDS) last year in 36 ARDS patients. Patients treated with MultiStem had:
Overall, the cells were well-tolerated with no serious adverse reactions within 24 hours of administration.
We saw a dramatic difference one year after patients received a single dose of MultiStem, Van Bokkelen said. We were really helping patients get on the path to recovery and get back to where they wanted to be in terms of functional independence and quality of life.
The company currently has two ongoing studies of MultiStem in ARDS patients: ONE-BRIDGE, a Phase II study in non-infection induced (pneumonitis) ARDS patients; and MACoVIA, a Fast Track designated Phase 2/3 study in COVID-19 induced ARDS patients.
ONE-BRIDGE, sponsored by HEALIOS K.K., is a randomized study aiming to enroll 35 adult participants to assess MultiStems safety and effects on ventilator-free days and various biomarkers. Enrollment is expected to be completed by the end of 2020.
MACoVIA is a randomized, placebo-controlled study designed to enroll up to approximately 400 adult participants to assess MultiStems safety and tolerability in COVID-19 ARDS patients, as well as evaluate its effect on ventilator-free days and all-cause mortality. We worked with the FDA to get study approval in an accelerated timeframe of a few months we started enrolling patients in early May, added Van Bokkelen. Were hoping to complete the study sometime next year.
We welcome the progress being made by Athersys to find a solution to the huge unmet need of ARDS treatment, Rubin commented. We hope that their Phase 3 trials are completely successful because this treatment is much needed. We support all companies engaging in research on treatment options for ARDS.
Read this article:
- Stemson Therapeutics Secures $7.5M Seed Financing for the Development of Breakthrough Hair Regeneration Therapy to Cure Hair Loss - Business Wire - September 18th, 2020
- Treatment, Access to Caregivers Among Factors Affecting QoL in MM - AJMC.com Managed Markets Network - September 18th, 2020
- Stemson Therapeutics Secures GBP6m in seed financing - Private Equity Wire - September 18th, 2020
- LabRoots Announces Speakers to Present Cutting-Edge Research Findings at its 4th Annual Cell Biology Virtual Conference - PR Web - September 18th, 2020
- California's $7.8 Billion Proposition 14 Could Expand Conflicts of Interest in Stem Cell Research | K. Lloyd Billingsley - The Beacon - September 16th, 2020
- Study focuses on new discovery in regenerative medicine - ANI News - September 16th, 2020
- New research connects the hormones we're born with to lifetime risk for immunological diseases - MSUToday - September 16th, 2020
- FDA Approves Study to Investigate the Use of Cell Therapy to Treat COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C) - PRNewswire - September 16th, 2020
- Global Regenerative Medicine Market Analysis & Forecast to 2025 - ResearchAndMarkets.com - Business Wire - September 15th, 2020
- Additional Analytical Results of the US-Based Phase 2b Clinical Trial of Regenerative Cell Medicine SB623 for the Treatment of Chronic Motor Deficit... - September 15th, 2020
- Proteins Role in Hair Cell Development Is Identified - Technology Networks - September 15th, 2020
- Researchers receive $16 million NIH grant to study link between autophagy and Alzheimer's disease - News-Medical.Net - September 15th, 2020
- Seeing the eye like never before | Newsroom - UW Medicine Newsroom - September 15th, 2020
- Ruxolitinib Appears Effective as Treatment of Steroid-Refractory GVHD - Targeted Oncology - September 13th, 2020
- $14.6M Grant to Explore a Therapy to Control HIV Without Meds - POZ - September 13th, 2020
- AgeX Therapeutics and Lineage Cell Therapeutics Announce Expansion of Agreement Related to ESI Clinical-grade Pluripotent Stem Cell Lines for... - September 11th, 2020
- Sernova to Participate in Cell and Gene Therapies for Chronic Conditions Panel at the Virtual 2020 Cell & Gene Meeting on the Mesa Conference -... - September 11th, 2020
- Plinabulin Granted FDA Breakthrough Therapy Designation for Chemotherapy-Induced Neutropenia - Targeted Oncology - September 11th, 2020
- Cancer Research Institute Announces Recipients of 2020 Philanthropy and Science Awards to Be Presented at Virtual Gala, Innovators in Science and... - September 11th, 2020
- Faculty of Medicine researchers receive $2.8m for equipment and infrastructure - UBC Faculty of Medicine - UBC Faculty of Medicine - September 8th, 2020
- BeyondSpring Receives Breakthrough Therapy Designations from Both U.S. FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia... - September 8th, 2020
- CC-486 Constitutes Standard of Care for Subset of Patients with AML - Targeted Oncology - September 7th, 2020
- Global Cell Therapy Market (2020 to 2025) - Growth, Trends, and Forecast - ResearchAndMarkets.com - Business Wire - September 7th, 2020
- Screening Natural Products as Therapeutics - Technology Networks - September 7th, 2020
- Interference between rhinovirus and influenza A virus: a clinical data analysis and experimental infection study - The Lancet - September 7th, 2020
- CRISPR-edited embryos should not be used. Not for the moment, that is - BioEdge - September 7th, 2020
- New HIV Gene Therapy, CAR-T Treatments Could be on the Horizon for Patients - BioSpace - September 4th, 2020
- Gene therapy research for HIV awarded $14.6 million NIH grant - USC News - September 4th, 2020
- Targeted Therapy for Non-Hodgkin Lymphoma: Current Progress and Future Plans - Cancer Therapy Advisor - September 4th, 2020
- Biopreservation Market share forecast to witness considerable growth from 2020 to 2025 | By Top Leading Vendors , STEMCELL Technologies, WAK-Chemie... - September 4th, 2020
- Gaining clarity on the ethical issues of a possible COVID-19 vaccine - Pursuit - September 4th, 2020
- Industrial Centrifuge Market worth $9.0 billion by 2025 - Exclusive Report by MarketsandMarkets - PRNewswire - September 4th, 2020
- BioForward Recognizes Scientific and Business Success with Annual Wisconsin Biohealth Awards - Business Wire - September 4th, 2020
- Dr. Kamii, DNP, APRN, FNP-BC wins Top Aesthetic Injector East in the Aesthetic Everything 2020 Aesthetic and Cosmetic Medicine Awards - PRNewswire - September 4th, 2020
- Worldwide Human Microbiome Immunology Therapeutics Industry to 2025 - The US Dominates the Global Market Landscape - PRNewswire - September 4th, 2020
- GoBroad Healthcare Group Showcases Innovative Hematologic Treatment Capabilities at the China Precision Medicine Forum - PRNewswire - August 29th, 2020
- Genetic mutations may be linked to infertility, early menopause - Washington University School of Medicine in St. Louis - August 29th, 2020
- COVID-19 Pandemic Impact on Global Stem Cell Therapy Market 2020-2024 | Technavio - Business Wire - August 29th, 2020
- The Road To Scale: Challenges Facing the Implementation of Animal-Free Recombinant Proteins Into Stem Cell Supply Chains - Technology Networks - August 29th, 2020
- Method regrows cartilage to cushion bones - Futurity: Research News - August 29th, 2020
- 5 Recent Tech Innovations Disrupting the Medical and Healthcare Industry - HealthTechZone - August 29th, 2020
- Auxolytic's Nutrient-Based Shut-Off Switch Boosts Cell Therapy Safety Without Transgenes - BioSpace - August 22nd, 2020
- 3D Cell Cultures Industry Report 2020-2025: Impact of COVID-19 on the World of Cell Culture - PRNewswire - August 22nd, 2020
- A bright future for genomics and gene therapy in the UK - Health Service Journal - August 22nd, 2020
- From stem cells to islets hope for treatment of type 1 diabetes - News - The University of Sydney - August 22nd, 2020
- Celularity Announces Sales of UltraMIST Ultrasound Healing Therapy Asset to Sanuwave Health, Inc. - PRNewswire - August 22nd, 2020
- McGill University researchers discover way to fight brain tumours' resistance to therapy - CTV News Montreal - August 22nd, 2020
- Regenerative medicine sector on pace for exceptional year - BioWorld Online - August 19th, 2020
- Medical Binocular Loupe Market Size 2020 - Application, Trends, Growth, Opportunities and Worldwide Forecast to 2025 - AlgosOnline - August 19th, 2020
- bluebird bio to Present New Data from Clinical Studies of elivaldogene autotemcel (eli-cel, Lenti-D) Gene Therapy for Cerebral Adrenoleukodystrophy... - August 19th, 2020
- Regenerative Medicine Market Is Expected To Gain Market Growth In The Forecast Period Of 2020 To 2027 | Emerging Players F. Hoffmann-La Roche Ltd,... - August 19th, 2020
- Novel CAR T-Cell Therapy Shows Promise in Advanced Hodgkin Lymphoma - Curetoday.com - August 16th, 2020
- Every Sumatran rhino has died in Malaysia. Scientists want to bring them back with cloning technology - CNN - August 14th, 2020
- Taipei hospital speeds up hearing checks and treatment - - August 14th, 2020
- Science News Roundup: Stem cells give hope for revival of Malaysia's extinct rhinos; Human versus disease showcased and more - Devdiscourse - August 14th, 2020
- Impact of COVID-19 on Global Stem Cell Assay Market Analysis, Growth Rate, Overview, Market Segmentation And Forecast By 2027 | Merck & Co.,... - August 14th, 2020
- Cell Expansion Market Research Report by Product, by Cell Type, by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19... - August 14th, 2020
- Potential Impact of COVID-19 Pandemic on Global Stem Cell Assay Coronavirus Impact Editon of Key Companies Merck, Thermo Fisher Scientific, GE... - August 9th, 2020
- Dad with incurable cancer takes on 300 mile cycle challenge ahead of stem cell transplant - HeraldScotland - August 9th, 2020
- Chromosomal Rearrangements Associated with Chemotherapeutic Drug Resistance | McDonnell Boehnen Hulbert & Berghoff LLP - JD Supra - August 9th, 2020
- Why Silicon Valley Execs Are Investing Billions to Stay Young - Robb Report - August 9th, 2020
- Regenerative meds and advanced therapies sector thriving despite COVID - The Pharma Letter - August 7th, 2020
- New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19 - GlobeNewswire - August 7th, 2020
- Mesoblasts share price gained another 16% in July. Heres why. - Motley Fool Australia - August 7th, 2020
- Celularity announces the activation of first California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19 - PRNewswire - August 5th, 2020
- COVID-19 Impacts: Hematopoietic Stem Cells Transplantation (HSCT) Market will Accelerate at a CAGR of Almost 6% Through 2020-2024 | Demand for... - August 5th, 2020
- IMAC Holdings Receives FDA Authorization to Initiate Clinical Study of Its Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for the Treatment... - August 5th, 2020
- Progenitor Cell-Based Market 2020-2026 is Slated to Witness Tremendous Growth || Leading Players BAXTER INTERNATIONAL INC, Boehringer Ingelheim... - August 5th, 2020
- CarthroniX President/Chairman of the Board R. Rex Parris and Carrol Parris Donate $50,000 in Support of Life Extension Research - PRNewswire - August 5th, 2020
- Sernova Enters into Exclusive Worldwide License Agreement with University of Miami for Therapeutic Cell Immune Protection Technologies -... - August 5th, 2020
- Electromedical Inc. Accelerates Corporate Expansion and Product DevelopmentAnnounces the Opening of First European Office For the Development of New... - August 5th, 2020
- More on the language of immunity - Cosmos - August 5th, 2020
- Gyroscope Announces Appointment of Leaders in Retinal Disease, Gene Therapy and the Complement System to Its Clinical and Scientific Advisory Boards -... - August 5th, 2020
- AlloVir raises $276M IPO to run broad cell therapy program - FierceBiotech - August 3rd, 2020
- A breakthrough: Stem cell therapy cures Covid-19 The Manila Times - The Manila Times - August 3rd, 2020
- Meso Numismatics Update on 2nd Transaction with Global Stem Cells - GlobeNewswire - August 3rd, 2020
- CAR-T Safe, Active in Hodgkin Lymphoma - MedPage Today - August 3rd, 2020
- Duvelisib May Reduce Lung Inflammation in Severe COVID-19 Cases - OncLive - August 3rd, 2020
- Regenerative Medicine Products to Discern Magnified Growth During 2019-2025 - Owned - August 3rd, 2020
- Global Cell Expansion Market, Forecast to 2025 - Increasing Incidence of Chronic Diseases and Government Investments for Cell-based Research -... - July 30th, 2020